Media Statements

This important medicine, and all associated activities, will be transferred to Eton Pharmaceuticals following the signing of an asset transfer agreement. This agreement is expected to complete at the end of 2024.

PARIS, FRANCE, 27 August 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has entered into an agreement to sell its rare pediatric disease Priority Review Voucher (PRV) to a large global pharmaceutical company. Ipsen received the PRV coinciding with the SohonosTM…

On Wednesday 21 June, David Loew was elected second Vice President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Yesterday’s appointments also included Lars Fruergaard Jørgensen, Chief Executive of Novo Nordisk, as EFPIA President, and Stefan Oelrich, Head…

Ipsen is committed to bringing innovative medicines to the rare disease community where a significant unmet need exists and innovation in treatments is lacking.